Erythropoietin
Links shared publicly online about this topic.
- 1,619total visits
Erythropoietin
View full resource at marvistavet.com
Tags: Anemia, Anemia Medication, Kidney Health, Urinary System, Kidney Disease, Kidney Failure, Procrit, Eprex
Most Recently Shared on November 8, 2009 at 12:28 am By:
anemic Zabor, with chronic renal failure & developed antibodies to erythropoietin http://bit.ly/14Zg42 receives 5 units of packed-cell blood
Multidose optimization simulation of erythropoie... [Pediatr Res. 2012] - PubMed - NCBI
ncbi.nlm.nih.gov — “PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on March 26, 2012 at 7:36 pm By:
Thomas Loarie, Jr Health Advocate
@medhealthnews Multidose optimization simulation of erythropoietin treatment in preterm infants. http://bit.ly/H86UsS #health #medicine
Medgenics to commence EPODURE Biopumps Phase IIa study in ESRD-related anemia
news-medical.net — “Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced receipt of clearance from the Israeli Ministry of Health to initiate a Phase IIa clinical study evaluating the safety and efficacy of sustained erythropoietin therapy produced and delivered by the Company's EPODURE Biopumps.” View full resource at news-medical.net
Most Recently Shared on March 26, 2012 at 4:52 am By:
Medgenics to commence EPODURE Biopumps Phase IIa study in ESRD-related anemia: Medgenics, Inc., the developer of... http://t.co/H0y4VuEt
Erythropoietin May Pose A Risk To Blood Vessels In The Brain And Body
medicalnewstoday.com — “Erythropoietin May Pose A Risk To Blood Vessels In The Brain And Body” View full resource at medicalnewstoday.com
Most Recently Shared on December 13, 2011 at 8:05 am By:
MNT Sports Medicine Health News
Erythropoietin May Pose A Risk To Blood Vessels In The Brain And Body http://t.co/KUNzR4Xz #sportsmedicine
EPO: Lighting the Fires of Cancer (HemoDoc, From Doctor to Patient)
hemodoc.com — “By Peter Laird, MD Erythropoietin (EPO) is a natural hormone that mediates the production of red blood cells (RBC's) that is primarily produced in the renal cortex and small amounts in the liver. Studies over the last decade evaluated the effects of EPO in diverse populations at risk of anemia outside of the renal dialysis patients, especially in patients undergoing chemotherapy for a variety of cancers. Unfortunately, these studies revealed adverse survival with more rapidly progressive cancers” View full resource at hemodoc.com
Most Recently Shared on December 9, 2011 at 2:33 am By:
The Kidney Group Nephrology and Physician Group
EPO: Lighting the Fires of Cancer http://t.co/mnfVKIZD
EPO Resistance May Predict Cardiovascular Events - Renal and Urology News
renalandurologynews.com — “Early identification of erythropoietin (EPO) resistance may help clinicians predict cardiovascular risk in hemodialysis (HD) patients, according to researchers.” View full resource at renalandurologynews.com
Most Recently Shared on December 5, 2011 at 3:41 pm By:
Renal Urology News Health News, Nephrology, Urology, and Medical Publisher
EPO Resistance May Predict Cardiovascular Events. http://t.co/wtYADVby #Hemodialysis #News #HCsm
Engineered, drug-secreting blood vessels reverse anemia in mice
sciencedaily.com — “Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers have demonstrated the possibility that blood vessels, made from genetically engineered cells, could secrete the drug on demand directly into the bloodstream. In a new study, they provide proof-of-concept, reversing anemia in mice with engineered vessels secreting erythropoietin (EPO).” View full resource at sciencedaily.com
Most Recently Shared on November 16, 2011 at 6:50 pm By:
UKRO Research and Nephrology
Engineered, drug-secreting blood vessels reverse anemia in mice - could be therapy 4 kidney patients 1 day. http://t.co/O728bZbx
Study Examines Blood Biomarkers Upon Erythropoietin Treatment of Ischemic Stroke | Biomarker Commons
biomarkercommons.org — “Researchers at the Max Planck Institute of Experimental Medicine in Goettingen, Germany, led by Prof. Hannelore Ehrenreich, the University of Bremen and University of Hannover, in collaboration with Dr.” View full resource at biomarkercommons.org
Most Recently Shared on September 29, 2011 at 4:45 pm By:
Ahead of print: neuropathic pain and ARW290, an erythropoietin analog « Ahead Of Print « Page2@Anesthesiology
page2anesthesiology.org — “Neuropathic pain is a difficult-to-treat pain disorder and may include allodynia, i.e., sensitivity to even non-painful stimuli. There is some evidence that…” View full resource at page2anesthesiology.org
Most Recently Shared on September 8, 2011 at 6:37 am By:
Pg 2 Anesthesiology Medical Publisher
Ahead of print: neuropathic pain and ARW290, an erythropoietin analog: animal study showed long term allodynia relief http://t.co/knLjVGO
Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial -- Ludman et al. 97 (19): 1560 -- Heart
heart.bmj.com — “Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial -- Ludman et al. 97 (19): 1560 -- Heart” View full resource at heart.bmj.com
Most Recently Shared on September 7, 2011 at 6:46 pm By:
Editor's Choice: Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomi... http://t.co/3ed3LVl
Ob/Gyn Article | Chemotherapy, Adjuvant Radiotherapy, Adjuvant Uterine Cervical Neoplasms
mdlinx.com — “Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: Results of the NoGGO-AGO Intergroup Study” View full resource at mdlinx.com
Most Recently Shared on August 24, 2011 at 2:20 pm By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa i... http://t.co/PkTgoSs #OBGYN
Oncology Article | Chemotherapy, Adjuvant Radiotherapy, Adjuvant Uterine Cervical Neoplasms
mdlinx.com — “Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: Results of the NoGGO-AGO Intergroup Study” View full resource at mdlinx.com
Most Recently Shared on August 24, 2011 at 8:41 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alf... http://t.co/y8S4GMA #oncology
Hormone reduces risk of heart failure from chemotherapy, study suggests
sciencedaily.com — “A new study utilizing a heart failure model is providing insight into one way to coax the cardiac stem cells into repairing the damaged heart. The research finds that low doses of erythropoietin (EPO), a hormone best known for controlling the production of red blood cells, might reduce the risk of heart failure associated with some anticancer therapies.” View full resource at sciencedaily.com
Most Recently Shared on August 4, 2011 at 10:03 pm By:
Endocrinology Wisdom OW Health
Hormone reduces risk of heart failure from chemotherapy, study suggests: A new study utilizing a heart failure m... http://bit.ly/n6SbkZ
Hormone reduces risk of heart failure from chemotherapy
eurekalert.org — “Now, a new study utilizing a heart failure model is providing insight into one way to coax the cardiac stem cells into repairing the damaged heart. The research, published by Cell Press in the August 2011 issue of the journal Cell Stem Cell, finds that low doses of erythropoietin (EPO), a hormone best known for controlling the production of red blood cells, might reduce the risk of heart failure associated with some anticancer therapies.” View full resource at eurekalert.org
Most Recently Shared on August 4, 2011 at 10:03 pm By:
Endocrinology Wisdom OW Health
Hormone reduces risk of heart failure from chemotherapy: ( Cell Press ) Now, a new study utilizing a heart failu... http://bit.ly/r38v8o
Hormone reduces risk of heart failure from chemotherapy, study suggests
sciencedaily.com — “A new study utilizing a heart failure model is providing insight into one way to coax the cardiac stem cells into repairing the damaged heart. The research finds that low doses of erythropoietin (EPO), a hormone best known for controlling the production of red blood cells, might reduce the risk of heart failure associated with some anticancer therapies.” View full resource at sciencedaily.com
Most Recently Shared on August 4, 2011 at 6:16 pm By:
ScienceDaily: Hormone reduces risk of heart failure from chemotherapy, study suggests http://bit.ly/pIFPRi Full http://bit.ly/omumDW
Serum resistin as a novel marker of erythropoietin... [Tohoku J Exp Med. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on August 1, 2011 at 11:50 pm By:
Serum resistin as a novel marker of erythropoietin resistance in nondiabetic patients on hemodialysis.: Authors:... http://bit.ly/nqRMeL
Advertisement
